Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet.
Bristol buys into the frenzy, and VEGF bispecific value inflation continues.
Evopoint reveals intriguing but opaque first-in-human data for XNW27011.
LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.
But camizestrant’s use could depend on uptake of monitoring – for now.
The company highlights the safety of its KLK2-targeting T-cell engager pasritamig.
